Targeted hydrolysis of beta-amyloid with engineered antibody fragments

Current Alzheimer Research

Volumn 7, Issue 3, 2010, Pages 214-222

  Kasturirangan, S ^a   Sierks, M ^b  

^a The Harrington Department of Bioengineering   (United States)

^b Arizona State University   (United States)

Author keywords

Secretase; Beta amyloid cleavage; Bispecific scFV; Proteolytic scfv; Serine protease

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; GAMMA SECRETASE; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PLASMIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; ATOMIC FORCE MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYDROLYSIS; IMMUNE RESPONSE; MENINGOENCEPHALITIS; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; DRUG DESIGN; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN FRAGMENTS; PROTEIN ENGINEERING;

EID: 77952524168     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791050876     Document Type: Article

References (73)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60(8): 1119-1122 (2003).
2. Goedert M, Spillantini MG, HJC, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8159-168 (1992).
3. Spillantini MG, Goedert M, Jakes R, Klug A. Different configurational states of ß-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci USA 87: 3947-3951 (1990).
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-356 (2002).
5. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline [see comments]. Jama 283(12): 1571-1577 (2000).
6. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408(6815): 975-979 (2000).
7. Nunan J, Small DH. Proteolytic processing of the amyloid-beta protein precursor of Alzheimer's disease. Essays Biochem 3837-49 (2002).
8. Wilson CA, Doms RW, Lee VM. Intracellular APP processing and A beta production in Alzheimer disease. J Neuropathol Exp Neurol 58(8): 787-794 (1999).
9. Beher D. Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery. Curr Top Med Chem 8(1): 34-37 (2008).
10. Barrow CJ, Zagorski MG. Solution Sturctures of ß-Peptide and Its constituent fragments: relation to amyloid deposition. Science 253 179-182 (1991).
11. Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 225 1075-1093 (1992).
12. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 733-736 (1987).
13. Golde TE, Estus S, Younkin LH, Selkoe DJ, SGY. Processing ofthe amyloid protein precursor to potentially amyloidogenic derivatives. Science 255: 728-730 (1992).
14. Estus S, Golde TE, Kunishita T, Blades D, Lowery D, Eisen M, et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 255: 726-728 (1992).
15. Yankner BA. Mechanisms of neuronal degeneration in alzheimer's disease. Neuron 16: 921-923 (1996).
16. Harper JD, Lansbury PTJ. Models of amyloid seeding in Alzheimer's disease and Scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407 (1997).
17. Harper JD, Wong SS, Lieber CM, Lansbury PTJ. Observation of metastable Aß amyloid protofibrils by atomic force microscopy. Chem Biol 4119-125 (1997).
18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95(11): 6448-6453 (1998).
19. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1): 106-113 (2008).
20. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-842 (2008).
21. Hock C, Konietzko U, Streffer JR, Tracy J, Andri S, Muller-Tillmanns B, et al. Antibodies against -amyloid slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554 (2003).
22. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-452. (2003).
23. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 89(4): 807-811 (2004).
24. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol Aging 23(6): 1009-1016 (2002).
25. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 5 Suppl 1055-1057 (2002).
26. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 420(6917): 879-884 (2002).
27. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9(12): 1520-1525 (2006).
28. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314(5799): 664-666 (2006).
29. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280(35): 30797-30806 (2005).
30. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2(7): 461-462 (2000).
31. Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS, et al. Gamma -secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 98(13): 7487-7491 (2001).
32. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18(2): 240-252 (2008).
33. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15): 8850-8855 (2001).
34. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6(2): 143-150 (2000).
35. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 100(10): 6221-6226 (2003).
36. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 292(5521): 1550-1552 (2001).
37. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100(7): 4162-4167 (2003).
38. Wang DS, Dickson DW, Malter JS. beta-Amyloid Degradation and Alzheimer's Disease. J Biomed Biotechnol 2006(3): 58406 (2006).
39. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43(5): 605-608 (2004).
40. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880): 535-539 (2002).
41. Hama E, Shirotani K, Iwata N, Saido TC. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J Biol Chem 279(29): 30259-30264 (2004).
42. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350(2): 113-116 (2003).
43. Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem 275(47): 36621-36625 (2000).
44. Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem 271(14): 8443-8451 (1996).
45. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1(6): 530-535 (2000).
46. Tucker HM, Simpson J, Kihiko-Ehmann M, Younkin LH, McGillis JP, Younkin SG, et al. Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. Neurosci Lett 368(3): 285-289 (2004).
47. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2(4): 417-423 (2002).
48. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 1(11): 859-866 (2002).
49. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126(Pt 9): 1935-1939 (2003).
50. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-ß attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177 (1999).
51. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8): 916-919 (2000).
52. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a substet of patients with AD after Ab42 immunization. Neurology 6146-54 (2003).
53. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 415(6871): 462 (2002).
54. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3(10): 824-828. (2002).
55. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21(3): 383-421 (2000).
56. Paul S, Nishiyama Y, Planque S, Karle S, Taguchi H, Hanson C, et al. Antibodies as defensive enzymes. Springer Semin Immunopathol 26(4): 485-503 (2005).
57. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283(8): 4714-4722 (2008).
58. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, et al. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 7(5): 391-397 (2008).
59. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271(37): 22908-22914 (1996).
60. Sun M, Gao QS, Kirnarskiy L, Rees A, Paul S. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J Mol Biol 271(3): 374-385 (1997).
61. Kim SH, Schindler DG, Lindner AB, Tawfik DS, Eshhar Z. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Mol Immunol 34(12-13): 891-906 (1997).
62. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunology Today 21(8): 397-402 (2000).
63. Gao QS, Sun M, Tyutyulkova S, Webster D, Rees A, Tramontano A, et al. Molecular cloning of a proteolytic antibody light chain. J Biol Chem 269(51): 32389-32393 (1994).
64. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 42(48): 14328-14334 (2003).
65. Liu R, McAllister C, Lyubchenko Y, Sierks MR. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry 43(31): 9999-10007 (2004).
66. Paul S, Tramontano A, Gololobov G, Zhou YX, Taguchi H, Karle S, et al. Phosphonate ester probes for proteolytic antibodies. J Biol Chem 276(30): 28314-28320 (2001).
67. Kasturirangan S, Brune D, Sierks M. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. Biotechnol Prog 25(4): 1054-1063 (2009).
68. Noel D, Bernardi T, Navarro-Teulon I, Marin M, Martinetto JP, Ducancel F, et al. Analysis of the individual contributions of immunoglobulin heavy and light chains to the binding of antigen using cell transfection and plasmon resonance analysis. J Immunol Methods 193(2): 177-187 (1996).
69. Taguchi H, Burr G, Karle S, Planque S, Zhou YX, Paul S, et al. A mechanism-based probe for gp120-Hydrolyzing antibodies. Bioorg Med Chem Lett 12(21): 3167-3170 (2002).
70. Barkhordarian H, Emadi S, Schulz P, Sierks MR. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel 19(11): 497-502 (2006).
71. Zameer A, Kasturirangan S, Emadi S, Nimmagadda SV, Sierks MR. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol 384(4): 917-928 (2008).
72. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26(1): 1-9 (2005).
73. Kontermann RE, Volkel T, Korn T. Production of recombinant bispecific antibodies. Methods Mol Biol 248 227-242 (2004).